Repligen Corp. (RGEN)
173.72
+3.70
(+2.18%)
USD |
NASDAQ |
Sep 02, 10:42
Repligen Research and Development Expense (Annual) : 51.31M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 51.31M |
| December 31, 2024 | 42.75M |
| December 31, 2023 | 42.61M |
| December 31, 2022 | 43.94M |
| December 31, 2021 | 32.88M |
| December 31, 2020 | 19.66M |
| December 31, 2019 | 19.45M |
| December 31, 2018 | 15.82M |
| December 31, 2017 | 8.672M |
| December 31, 2016 | 7.355M |
| December 31, 2015 | 5.74M |
| December 31, 2014 | 5.609M |
| December 31, 2013 | 7.341M |
| December 31, 2012 | 10.49M |
| December 31, 2011 | 12.62M |
| March 31, 2010 | 14.16M |
| Date | Value |
|---|---|
| March 31, 2009 | 12.77M |
| March 31, 2008 | 7.241M |
| March 31, 2007 | 5.924M |
| March 31, 2006 | 5.163M |
| March 31, 2005 | 5.037M |
| March 31, 2004 | 6.484M |
| March 31, 2003 | 5.226M |
| March 31, 2002 | 5.361M |
| March 31, 2001 | 5.786M |
| March 31, 2000 | 3.754M |
| March 31, 1999 | 1.847M |
| March 31, 1998 | 1.420M |
| March 31, 1997 | 1.927M |
| March 31, 1996 | 10.88M |
| March 31, 1995 | 28.41M |
| March 31, 1994 | 33.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| BioLife Solutions, Inc. | 7.566M |
| Danaher Corp. | 1.598B |
| Liquidia Corp. | 38.45M |
| Harmony Biosciences Holdings, Inc. | 189.59M |
| Agilent Technologies, Inc. | 450.00M |